David Hutton


Re-Vana Therapeutics raises $11.9 million in Series A financing for development of ophthalmic therapeutics

Re-Vana has demonstrated that its platform can achieve 6 months or greater sustained delivery of an anti-VEGF biologic at therapeutically-relevant levels with high drug loading, controlled burst release, and a favorable degradation profile.

Harrow and iOR Partners expand national product supply agreement

The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

UCI-led study shows repeated stress accelerates aging of the eye

According to investigators, retinal aging caused by stress produces symptoms similar to those resulting from natural aging.

Patricia Piers, PhD, discusses a career of innovation in ophthalmology, looks to future

November 28, 2022

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

Alcon completes acquisition of Aerie Pharmaceuticals

November 22, 2022

The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.

Oculis highlights positive phase 2 data investigating topical anti-TNFα agent licaminlimab in acute anterior uveitis

November 22, 2022

Oculis SA has published positive data of its licaminlimab active-controlled, multicenter, randomized, parallel-group Phase 2 clinical trial assessing the effect of topical licaminlimab on anterior chamber (AC) cell grade in patients with acute anterior uveitis.